Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good evening, ladies and gentlemen, and welcome to the Verica Pharmaceuticals First Quarter 2025 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may begin your conference. Thank you, Operator. Hello, everyone, and welcome to Verica Pharmaceuticals' first quarter 2025 Corporate Update Conference Call. With me on the line this evening are Jason Rieger, President and Chief Executive Officer of Verica Pharmaceuticals, Noah Rosenberg, Chief Medical Officer, John Kirby, Interim Chief Financial Officer, and David Zawitz, Chief Operating Officer. As a reminder during today's call, management will make forward-looking statements. These statements may include expectations related to the commercialization of WICAN for the treatment of molluscum contagiosum in the United States, continued revenue growth, regulatory developments, the development of Verica's product candidates, the company's expected cash runway, and its ability to obtain funding for future operations. and Verica's overall business strategy and planned operations. These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. And based on those risks and uncertainties, Verica's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. Please see Verica's SEC filings for important risk factors. Verica cautions you not to place undue reliance on forward-looking statements and undertakes no duty or obligation to update any forward-looking statem...